Olema Pharmaceuticals
Yahoo Finance • 22 days ago
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the stocks highlighted in Jim Cramer’s latest Mad Money recap as he provided top stock insights. Answering a caller’s query about the stock, Cramer said: Too risky for me. I just think t... Full story
Yahoo Finance • 24 days ago
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
On February 17, 2026, Paradigm Biocapital Advisors LP disclosed a buy of 750,000 shares of Olema Pharmaceuticals(NASDAQ:OLMA) in Q4 2025, an estimated $13.35 million trade based on quarter-end pricing. What happened According to a Securi... Full story
Yahoo Finance • 29 days ago
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
SAN FRANCISCO, March 17, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targete... Full story
Yahoo Finance • 30 days ago
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Key Points Cormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter. The value of the position was $68.75 million at quarter-end. The new position places Olema outside... Full story
Yahoo Finance • last month
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story
Yahoo Finance • last month
A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Olema Pharmaceuticals (OLMA) is back in focus after Roche’s Phase 3 breast cancer trial for giredestrant missed its pr... Full story
Yahoo Finance • last month
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02
H.C. Wainwright notes that Roche’s (RHHBY) persevERA trial “disappointingly” failed, though the firm does not view the frontline opportunity as eliminated for palazestrant and does not believe the persevERA trial is “a complete readthrough... Full story
Yahoo Finance • 2 months ago
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targete... Full story
Yahoo Finance • 2 months ago
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating
Olema Pharmaceuticals (NASDAQ:OLMA) is one of the 17 biotechnology stocks with more than 50% upside. On February 11, Laura Prendergast of Stifel Nicolaus initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA). She assigned a Buy rating... Full story
Yahoo Finance • 4 months ago
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT
We recently published 10 Stocks Boasting the Biggest Gains; 4 Hit Record Highs. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the best performers on Wednesday. Olema bounced back on Wednesday to hit a new four-year high as investors... Full story
Yahoo Finance • 4 months ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story
Yahoo Finance • 5 months ago
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targete... Full story
Yahoo Finance • 5 months ago
Commit To Purchase Olema Pharmaceuticals At $16, Earn 40.4% Annualized Using Options
Investors eyeing a purchase of Olema Pharmaceuticals Inc (Symbol: OLMA) shares, but tentative about paying the going market price of $20.88/share, might benefit from considering selling puts among the alternative strategies at their dispos... Full story
Yahoo Finance • 5 months ago
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story
Yahoo Finance • 5 months ago
Biotech Stock Gets Booted in Latest Fund Update
Key Points Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift These 10 st... Full story
Yahoo Finance • 5 months ago
Olema Pharmaceuticals (OLMA) Rethinks Competitive Edge After Roche’s Breast Cancer Trial Success
Roche recently announced positive Phase 3 trial results for its breast cancer therapy, giredestrant, which operates through a mechanism that directly parallels Olema Pharmaceuticals’ lead candidate, palazestrant. This development has been... Full story
Yahoo Finance • 5 months ago
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story
Yahoo Finance • 5 months ago
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 130%
Biotech stock Olema Pharmaceuticals catapulted to a four-year high Tuesday after Roche unveiled positive results in breast cancer treatment. Continue Reading View Comments... Full story
Yahoo Finance • 5 months ago
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination withatirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline E... Full story
Yahoo Finance • 5 months ago
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted... Full story
